PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

K. Gopal, Ajay; S. Kahl, Brad; de Vos, Sven; D. Wagner‐Johnston, Nina; J. Schuster, Stephen; Jurczak, Wojciech; W. Flinn, Ian; R. Flowers, Christopher; Martin, Peter; Viardot, Andreas; A. Blum, Kristie; Goy, André; Davies, Andrew; Luigi Zinzani, Pier; Dreyling, Martin; Johnson, Dave; L. Miller, Langdon; Holes, Leanne; Li, Daniel; Dansey, Roger; R. Godfrey, Wayne; Salles, Gilles

doi:10.1056/nejmoa1314583

Public

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

Published in New England Journal of Medicine • Jan 22, 2014

Authors:

Ajay K. Gopal

Brad S. Kahl

Sven de Vos

Abstract

BACKGROUND: Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ inhibitor, showed antitumor activity in ...

Subject

Idelalisib

PI3K/AKT/mTOR pathway

Lymphoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!